Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

    ... Azacitidine Lenalidomide Phase:  ... is a restricted distribution program for receiving lenalidomide ) Females of childbearing potential (FCBP)† must have a ...

    Clinical Trial last updated 06/06/2016 - 1:30pm.

  2. Incidence and Burden of the Myelodysplastic Syndromes

    ... despite strong evidence that hypomethylating agents and lenalidomide significantly reduce transfusion burden. Other unmet needs ...

    Research Article last updated 10/14/2015 - 8:44am.

  3. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... the US Food and Drug Administration for its treatment: lenalidomide , 5- azacitidine , and decitabine . These ...

    Research Article last updated 05/26/2015 - 12:13pm.

  4. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or ... outcomes in these patients are needed. Azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and ...

    Research Article last updated 06/28/2013 - 1:24pm.

  5. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 05/12/2015 - 9:47am.

  6. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... p53 expression status known to confer resistance to lenalidomide in low-risk del(5q) MDS might also influence response to ...

    Research Article last updated 07/07/2014 - 9:27am.

  7. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... therapies, such as azacitidine or lenalidomide . The recombinant human erythropoietin (rHuEPO) ...

    Research Article last updated 03/04/2015 - 10:20am.

  8. More is better: Combination therapies for myelodysplastic syndromes

    ... are currently three FDA-approved medications for MDS; lenalidomide , azacitidine , and decitabine . The role of ...

    Research Article last updated 03/03/2015 - 2:41pm.

  9. Established and novel agents for myelodysplastic syndromes

    ... abnormality or those who fail these initial approaches, lenalidomide may be tried, as can experimental agents. Lower-risk patients ...

    Research Article last updated 03/03/2015 - 1:10pm.

  10. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 01/20/2015 - 12:52pm.